Skip Nav Destination
Issues
1 May 2009
-
Cover Image
Cover Image
The cover image shows a false color map indicating areas most likely to contain neoplasia superimposed on a corresponding white-light photograph of a suspicious oral lesion (this image is a detail of the full oral-cavity image depicted on this page). The probability of neoplasia is computed from an autofluorescence image of the same site; the diagnostic algorithm was developed from clinical-study data involving autofluorescence images from 67 subjects. The map is color coded so that bright orange and white areas indicate areas with the highest probability of neoplasia; histologic analysis revealed that these areas corresponded to moderate dysplasia and carcinoma in situ. Autofluorescence image analysis highlighted areas of pathologically confirmed dysplasia and cancer, which were not readily visible under standard white-light inspection. Autofluorescence images in conjunction with a classification algorithm had 100 % sensitivity and 91.4 % specificity for discriminating dysplastic and cancerous lesion areas from normal areas. See articles by Roblyer et al. (beginning on page 423), Poh et al. (beginning on page 401), and Kelloff, Sigman and Contag (beginning on page 405) for more information. - PDF Icon PDF LinkTable of Contents
ISSN 1940-6207
EISSN 1940-6215
Issue Sections
Perspective
Different Perspective
Review
Minireview
Research Articles
A Randomized Phase II Chemoprevention Trial of 13-CIS Retinoic Acid with Or without α Tocopherol or Observation in Subjects at High Risk for Lung Cancer
Karen Kelly; John Kittelson; Wilbur A. Franklin; Timothy C. Kennedy; Catherine E. Klein; Robert L. Keith; Edward C. Dempsey; Marina Lewis; Mary K. Jackson; Fred R. Hirsch; Paul A. Bunn; York E. Miller
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.